Cancer of Gastrointestinal Tract
8
3
4
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (8)
Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Tempus Priority Study: A Pan-tumor Observational Study
Rare Subtypes of Gastrointestinal Cancers
Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers
Exercise Regimens and Neoadjuvant Chemotherapy
Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas